Saidal group announced today, Monday, the start of insulin production in the first quarter of 2023, in implementation of the directives given by the President of the Republic, Mr. Abdelmadjid Tebboune during the cabinet meeting he chaired yesterday Sunday.
The group said in a statement that it will start the production of insulin (solutions and injections) in the Constantine 1 factory, with a production capacity of one million vials per year.
It’s worth noting thatthe President of the Republic gave instructions, during the cabinet meeting, to produce children’s vaccines and insulin in Algeria, as from 2023, as well as to combat drug smuggling in all its forms, and to impose the most severe penalties on those involved in this crime.
The group affirmed that it intends in 2023, with the support of the Ministry of Pharmaceutical Industry, “to live up to the aspirations of the President of the Republic, especially those related to covering the national market and ensuring the provision of medicines to the Algerian citizen with local production.”
The President of the Republic also gave, during the Council of Ministers, directives to rehabilitate the “Saidal” group to ensure the coverage of a large part of the needs of the national market, “after it had retreated to 5 percent after having 47% of the market before.
Exporting to 10 African countries in 2023 and investing abroad
Meanwhile, the group announced that “2023 will also be a year of export”, as “Saidal” aims to ensure the supply of medicines to Africa, by registering its products in more than 10 African countries, and “the group is currently planning to export to other countries such as Venezuela.”
In addition to exporting, Sidal aims to develop its activities “by investing outside Algeria, in other African countries,” according to the statement.
The company’s share in the market also developed from 3 percent in 2019 to 9 percent in 2022, and it looks forward – according to the statement – to double it in 2024.
